Search results for "Monoclonal B-cell lymphocytosis"

showing 2 items of 2 documents

Association of polygenic risk score with the risk of chronic lymphocytic leukemia and monoclonal B-cell lymphocytosis

2018

IF 15.132 (2017); International audience; Inherited loci have been found to be associated with risk of chronic lymphocytic leukemia (CLL). A combined polygenic risk score (PRS) of representative single nucleotide polymorphisms (SNPs) from these loci may improve risk prediction over individual SNPs. Herein, we evaluated the association of a PRS with CLL risk and its precursor, monoclonal B-cell lymphocytosis (MBL). We assessed its validity and discriminative ability in an independent sample and evaluated effect modification and confounding by family history (FH) of hematological cancers. For discovery, we pooled genotype data on 41 representative SNPs from 1499 CLL and 2459 controls from the…

AdultMale0301 basic medicineOncologymedicine.medical_specialtyLymphocytosisClinical Trials and ObservationsChronic lymphocytic leukemiaImmunologySingle-nucleotide polymorphism[SDV.CAN]Life Sciences [q-bio]/CancerLymphocytosisPolymorphism Single NucleotideBiochemistry03 medical and health sciences0302 clinical medicineRisk Factorsimmune system diseasesInternal medicinehemic and lymphatic diseasesGenotypeOdds RatiomedicineHumansGenetic Predisposition to Disease10. No inequalityAgedAged 80 and overB-Lymphocytesbusiness.industryConfoundingCell BiologyHematologyOdds ratioMiddle Agedmedicine.diseaseLeukemia Lymphocytic Chronic B-Cell3. Good health030104 developmental biologyGenetic epidemiologyGenetic Loci030220 oncology & carcinogenesisMonoclonal B-cell lymphocytosisFemalemedicine.symptombusiness
researchProduct

Differentiation on Biological Basis of Monoclonal B-Cell Lymphocytosis (MBL) From Chronic Lymphocytic Leukemia (CLL): Results of a Prospective GISL (…

2010

Abstract Abstract 1360 The arbitrary cut-off of 5000/μL chronic lymphocytic leukemia (CLL)-phenotype cells in peripheral blood is generally used to separate monoclonal B-cell lymphocytosis (MBL) from CLL. However, a major concern is the biological differentiation, if any, between MBL and CLL. We tried to address the issue therefore analyzing 261 Rai stage 0 patients enrolled in a Gruppo Italiano Studio Linfomi (GISL) prospective multicentre trial designed to validate biological parameters in early CLL as well as to assess the impact on clinical outcome of an early versus delayed policy of treatment with subcutaneous alemtuzumab in the high biological risk. In this cohort, biological charact…

Oncologymedicine.medical_specialtyLymphocytosisbusiness.industryChronic lymphocytic leukemiaImmunologyCell BiologyHematologymedicine.diseaseBiochemistryPeripheral bloodhemic and lymphatic diseasesInternal medicineMonoclonalCohortmedicineAlemtuzumabMonoclonal B-cell lymphocytosisStage (cooking)medicine.symptombusinessmedicine.drugBlood
researchProduct